In particular, the enzyme O-GlcNAcase (OGA) is a promising target for such small-mol­ecule inhibitors, since the level of O-GlcNAc in our body influences diseases such as Alzheim­er’s (Yuzwa et al., 2012 ▸) or cancer (Ma & Vosseller, 2013 ▸). The gene discussed is OGA; the disease is cancer.